San­doz an­tic­i­pates ad­di­tion­al $3B in po­ten­tial net sales over five years in pipeline ex­pan­sion

San­doz to­day gave in­sight in­to its over­all strat­e­gy once it be­comes an in­de­pen­dent com­pa­ny lat­er this year, in­clud­ing plans to ex­pand its work in biosim­i­lars and build rev­enue af­ter claim­ing $9.1 bil­lion in sales last year.

The gener­ics mak­er and cur­rent No­var­tis di­vi­sion host­ed a cap­i­tal mar­kets day in New York City on Thurs­day — the first of two such days, with the sec­ond one planned for Lon­don next week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.